Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions

NCT01011634
View directory record Official record
Conditions
Undesired Intrauterine Pregnancy, First Trimester Pregnancy
Interventions
Intravenous moderate sedation versus oral medication
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
View directory record Official record
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

NCT00578214
View directory record Official record
Conditions
Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
Interventions
Randomized Midazolam, Placebo, Local Anesthesia, Prospective Midazolam
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Results available

Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation

NCT01519167
View directory record Official record
Conditions
Ultrasound, CT Scans, MRIs
Interventions
Dexmedetomidine, Midazolam, Fentanyl
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Weeks to 16 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Little Rock, Arkansas • Anaheim, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Midazolam, Caffeine, Bupropion
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Virtual Reality as a Substitute for Procedural Sedation During Epidural Steroid Injections

NCT04887285
View directory record Official record
Conditions
Lower Back Pain, Lumbar Radiculopathy
Interventions
Virtual reality, Intravenous sedation, Standard care
Device · Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 19, 2026, 1:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03436485
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ODM-208, Midazolam
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol and Midazolam Metabolism

NCT01173640
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, resveratrol (single dose), resveratrol (multiple dose)
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 19, 2026, 1:07 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

NCT06632990
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
BMS-984923, Midazolam, Caffeine, dextromethorphan
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 19, 2026, 1:07 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Intranasal Dexmedetomidine

NCT02985697
View directory record Official record
Conditions
Safety and Efficacy of Intranasal Dexmedetomidine
Interventions
Dexmedetomidine, Midazolam Hydrochloride, Nitrous Oxide
Drug
Lead sponsor
Bon Secours Pediatric Dental Associates
Other
Eligibility
3 Years to 6 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

NCT00258050
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Midazolam, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue

NCT04141696
View directory record Official record
Conditions
Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Pediatric Dental Oral Sedation Outcomes With and Without Meperidine in Children Aged 3-7 Years

NCT04068948
View directory record Official record
Conditions
Dental Caries in Children, Pediatric Dental Sedation, Meperidine, Hydroxyzine, Midazolam
Interventions
Meperidine, Hydroxyzine, Midazolam
Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years to 7 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

NCT01827540
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Cenicriviroc, Dolutegravir, Midazolam
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3522348 in Healthy Participants

NCT04559568
View directory record Official record
Conditions
Healthy
Interventions
LY3522348, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

NCT05338476
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

NCT07103720
View directory record Official record
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 2 Interventional

Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS

NCT00579085
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
Ketamine, IV NSS, Normal Saline
Drug · Other
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

NCT04392011
View directory record Official record
Conditions
Interaction Drug Food
Interventions
Midazolam HCl, Dextromethorphan HBr, Kratom
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 1:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients

NCT00417664
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Propofol, Midazolam
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 19, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 19, 2026, 1:07 PM EDT